Outlook Therapeutics, Inc.

OTLK

NASDAQ

Healthcare

Biotechnology

Iselin, NJ, US23 employeesoutlooktherapeutics.com

$0.21

+0.01(2.38%)

Mkt Cap $9M

$0.20

$2.97

52-Week Range

At a Glance

AI-generated

8-K

Outlook Therapeutics, Inc. closed a best-efforts public offering on March 25, 2026, of 20,000,000 shares of common stock and accompanying warrants to purchase 20,000,000 shares at a combined price of $0.25, raising approximately $5.0 million in gross proceeds and $4.0 million in net proceeds. This financing provides capital but involves substantial dilution from new shares and exercisable warrants.

$9M

Market Cap

$140.4K

Revenue

-$70M

Net Income

Employees23

Fundamentals

How The Business Makes Money

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Industry Biotechnology

Activity

What Changed Recently

Management Change

Mar 10, 2026

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 6, 2

Delisting

Feb 17, 2026

. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing . On February 18, 2026, Outlook Therapeutics, Inc., a Dela

Material Agreement

Mar 15, 2026

Entry into a Material Definitive Agreement. On March 16, 2026, Outlook Therapeutics, Inc. (the “Company”) entered into a Note Purchase Agreement (the “NPA”) wit

Financial Results

Feb 16, 2026

and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”

Other Event

Mar 24, 2026

Other Events. On March 23, 2026, Outlook Therapeutics, Inc. (the “Company”) commenced a best-efforts public offering (the “Offering”) of its common stock and ac

Peer Companies

Company	Price	Change	Market Cap	P/E
IPSCCentury Therapeutics, Inc...	$2.15	-2.05%	$186M	-21.4
EQEquillium, Inc.	$1.97	-3.43%	$70M	-3.0
HOWLWerewolf Therapeutics, In...	$1.00	+4.86%	$49M	-0.5
OSTXOS Therapies Incorporated	$1.37	+0.74%	$48M	—
COEPCoeptis Therapeutics Hold...	$11.94	+5.85%	$42M	-3.9
SPRBSpruce Biosciences, Inc.	$71.00	+2.11%	$41M	-1.2
NRXPNRx Pharmaceuticals, Inc.	$2.20	+1.85%	$38M	-1.0
CUECue Biopharma, Inc.	$0.18	-11.20%	$14M	-1.1

Analyst View

Company Profile

CIK0001649989

ISINUS69012T3059

CUSIP69012T206

Phone609 619 3990

AddressBuilding F, Iselin, NJ, 08852, US

SEC EDGAR